FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

vvasnington,	D.C. 20549

Check this box if no longer subject	S
to Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB N	OMB Number: 3235-0287							
Estimated average burden								
hours	er response	e: 0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Porter Andy  (Last) (First) (Middle)					Suer Name and Ticker or Trading Symbol Relay Therapeutics, Inc. [ RLAY ]      Date of Earliest Transaction (Month/Day/Year)									k all app Direct Office	tionship of Reportir all applicable) Director Officer (give title below)		rson(s) to Is 10% Ov Other (s below)	vner	
C/O RELAY THERAPEUTICS, INC. 399 BINNEY ST., 2ND FLOOR					04/2	04/28/2022								6 Ind	Chief Administrative Officer				
(Street) CAMBR (City)			)2139 Zip)		4. 11 /									Line)					
(- 9)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day				tion	ion 2A. Deemed Execution Date,		3. Transaction Code (Instr. 8)  4. Securities Disposed Of 5)			s Acqu	ired (A	or 5. Amo 4 and Securit Benefic		unt of ies cially Following	Form (D) o	n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	v	Amount	(A) (D)	Pr	ice	Transa	ection(s) 3 and 4)			(111341. 4)		
Common Stock 04/28/2				2022		S		435(1)	D	\$2	25.57 4		5,588(2)		D				
		Та	ble II -								osed of, convertib				Owned	t			
1. Title of Derivative Security (Instr. 3)	Title of 2. 3. Transaction Date Execution Date, or Exercise (Month/Day/Year)				. 5. Number of Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		De Se (In	Price of crivative curity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transactio (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4		Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Numb of Share	··					

## **Explanation of Responses:**

1. Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 1,510 shares of restricted stock units ("RSUs") on April 27, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.

## Remarks:

/s/ Brian Adams, as attorney-

05/02/2022

in-fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>2.</sup> Includes 33,160 shares underlying RSUs.